Phase II Study: Treatment of Non-Hodgkin's Lymphoma With an Oral Antitumor Derivative of Bis(2,6-dioxopiperazine)
العنوان: | Phase II Study: Treatment of Non-Hodgkin's Lymphoma With an Oral Antitumor Derivative of Bis(2,6-dioxopiperazine) |
---|---|
المؤلفون: | Yasushi Ikeda, Masao Tanaka, Mitomo Y, Kazumasa Yamada, Kiyoji Kimura, Osamu Kamiya, Yoshihisa Kodera, Yokomaku S, Shigeru Shirakawa, Ryuzo Ohno, Takashi Oguri, Hidehiko Saito, Masami Hirano, Masahide Kobayashi |
المصدر: | JNCI: Journal of the National Cancer Institute. 84:435-438 |
بيانات النشر: | Oxford University Press (OUP), 1992. |
سنة النشر: | 1992 |
مصطلحات موضوعية: | Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, Vincristine, Adolescent, Cyclophosphamide, medicine.medical_treatment, Administration, Oral, Phases of clinical research, Antineoplastic Agents, Piperazines, Internal medicine, medicine, Humans, Doxorubicin, Etoposide, Aged, Aged, 80 and over, Chemotherapy, business.industry, Lymphoma, Non-Hodgkin, Combination chemotherapy, Middle Aged, medicine.disease, Non-Hodgkin's lymphoma, Drug Evaluation, Female, business, medicine.drug |
الوصف: | BACKGROUND Although razoxane (ICRF-159), a derivative of bis(2,6-dioxopiperazine), has shown significant antitumor activity in several murine tumors, inadequate bioavailability has limited its clinical efficacy. Sobuzoxane (MST-16), another derivative of bis(2,6-dioxopiperazine), has shown activity against a broad spectrum of murine tumors and human tumor xenografts in nude mice and a lack of cross-resistance to vincristine, doxorubicin, cyclophosphamide, fluorouracil, etoposide, and mitomycin C. These findings suggest that MST-16 has a mode of cytocidal activity different from that of other antitumor agents. PURPOSE The present late phase II study was conducted to evaluate the clinical efficacy and toxicity of MST-16 in non-Hodgkin's lymphoma (NHL). METHODS As part of a multi-institutional cooperative study, we conducted a study of MST-16 in 27 patients with NHL who were assessable for drug efficacy and toxicity. MST-16, a bis(2,6-dioxopiperazine) analogue and an inhibitor of topoisomerase II, was administered orally at a dose of 1600 mg/m2 a day for 5-7 days at intervals of 2-3 weeks. RESULTS Response consisted of one complete remission and seven partial remissions in 27 assessable patients. Response was achieved at a median of 13 days (range, 9-62 days) after initiation of therapy and lasted a median of 46 days (range, 29-155 days). Major toxic effects were leukopenia in 70% of the patients, thrombocytopenia in 44%, and gastrointestinal disorders in 37%. CONCLUSIONS MST-16 was shown to be effective in NHL and deserves further clinical trial, since the drug shows little cross-resistance to available antitumor drugs. IMPLICATIONS Phase II clinical studies of MST-16 in treatment of breast cancer, gastric cancer, and adult T-cell leukemia and lymphoma are also being conducted in Japan. Future trials of combination chemotherapy using MST-16 with other antitumor drugs are warranted in view of the additive effects observed in studies of MOLT-3 cells and studies of L1210 leukemia in mice. |
تدمد: | 1460-2105 0027-8874 |
URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6893a0f29ddb0d842cf799894d58d775 https://doi.org/10.1093/jnci/84.6.435 |
رقم الأكسشن: | edsair.doi.dedup.....6893a0f29ddb0d842cf799894d58d775 |
قاعدة البيانات: | OpenAIRE |
تدمد: | 14602105 00278874 |
---|